By Dr Chun Tang — MBChB (Manchester), MRCGP, MBA · Practising NHS & Private GP · Founder, Little Ox

NMN and Menopause: What the Clinical Evidence Actually Shows

Of all the areas where NMN research intersects with women's health, menopause is where the clinical evidence is arguably strongest and most directly relevant. This isn't a case of extrapolating from animal models or applying general longevity research tangentially. There are specific human trials, specific biological mechanisms, and specific symptom clusters where the evidence points clearly — if you know where to look.

As a GP who has had this conversation with many patients, I want to explain what the science actually shows, because the menopause conversation in the UK is finally getting the serious clinical attention it deserves.

The Biology: Why Menopause and NAD+ Decline Are Connected

NAD+ decline is a continuous process from the mid-30s onwards — roughly 1–2% per year. This is well established. What is less widely discussed is the specific relationship between oestrogen and NAD+ biosynthesis.

Oestrogen plays a direct regulatory role in several NAD+ biosynthetic enzymes, including those in the salvage pathway that recycles nicotinamide back into NAD+. As oestrogen levels fall during perimenopause, this regulatory support is withdrawn, and NAD+ production efficiency declines further — on top of the standard age-related decline already in progress.

The result is a compounding effect that is specific to women and specific to the perimenopausal transition: age-related NAD+ decline, accelerated by oestrogen-mediated disruption to NAD+ biosynthetic pathways, at precisely the time when the body is managing the most significant hormonal upheaval of adult life.

This is not a theoretical concern. A 2024 study published in MedComm examining NAD+ in aging ovaries found that ovarian NAD+ levels decline significantly with age, and that NMN administration restored these levels, preventing ovarian atrophy, improving mitochondrial function in ovarian cells, and reducing ovarian inflammation. This was an animal study — but the mechanism is directly relevant to understanding what is happening at a cellular level during the human menopause transition.

The Landmark Human Trial: Postmenopausal Women and Insulin Sensitivity

The most directly relevant human clinical trial for NMN and menopause was published in Science in 2021 — one of the most rigorous journals in medicine. The trial was a 10-week, randomised, placebo-controlled, double-blind study testing NMN supplementation in 25 postmenopausal women with prediabetes who were overweight or obese.

The results were significant. NMN supplementation improved muscle insulin sensitivity — assessed by hyperinsulinemic-euglycemic clamp, the gold standard method — and increased skeletal muscle insulin signalling (AKT and mTOR phosphorylation). NMN also up-regulated genes related to muscle remodelling.

This matters specifically for postmenopausal women because metabolic dysfunction — particularly insulin resistance and the associated risk of type 2 diabetes, cardiovascular disease and weight gain — accelerates significantly after menopause. The loss of oestrogen's protective effects on insulin sensitivity creates a metabolic vulnerability that is one of the most clinically significant long-term consequences of the menopause transition. The 2021 Science trial demonstrated that NMN can improve exactly this parameter in exactly this population.

Notably, a parallel trial testing NR (Nicotinamide Riboside, the other major NAD+ precursor) in men showed no improvement in insulin sensitivity. This points to a sex-specific benefit of NMN that is particularly relevant to postmenopausal women — and aligns with animal research showing that NMN prolongs lifespan in female but not male mice.

Energy, Fatigue and the Menopause Experience

Fatigue is one of the most commonly reported and least adequately addressed menopause symptoms. It's multifactorial — disrupted sleep, hormonal fluctuation, psychological burden — but it also has a direct cellular component.

Mitochondrial function in muscle and brain tissue declines as oestrogen falls, and NAD+ availability is a key variable in that decline. The "running on empty" experience that many perimenopausal and postmenopausal women describe — particularly the mid-afternoon energy crash and the disproportionate fatigue after activity that used to be manageable — has a real cellular basis in mitochondrial energy deficits.

A 2024 randomised controlled trial found that NMN supplementation improved physical performance (six-minute walking test) and quality of life scores (SF-36) significantly compared to placebo in middle-aged adults. The same trial confirmed NAD+ levels rose substantially at 300mg, 600mg and 900mg doses. A second 2024 trial specifically found NMN improved afternoon fatigue and lower limb function — outcomes that map directly onto what menopausal women report.

Sleep — Arguably the Most Important Dimension

Sleep disruption in menopause is near-universal. Hot flushes interrupt sleep architecture. Anxiety and mood changes resist sleep onset. The decline in progesterone — which has direct GABAergic (calming) effects — reduces recovery and overnight routine independent of vasomotor symptoms.

NAD+ is directly involved in regulating the circadian clock genes that govern sleep-wake cycles, and declining NAD+ levels are associated with disrupted circadian signalling. A 2024 randomised, placebo-controlled, double-blind trial found that NMN supplementation significantly improved recovery and overnight routine scores, including reductions in daytime dysfunction and global sleep impairment, in older adults after 12 weeks.

This is one of the more practically meaningful findings for menopausal women. HRT remains the most effective treatment for vasomotor symptoms and many other aspects of menopause management, but sleep improvement is an area where cellular support can meaningfully complement hormonal approaches — particularly for women for whom HRT is not appropriate or desired.

Skin, Hair and Collagen

Skin and hair changes are among the most visible manifestations of the menopause transition. Collagen production decreases as oestrogen falls — skin loses elasticity, becomes thinner, and heals more slowly. Hair texture changes and increased hair loss are widely reported.

NAD+ supports sirtuin activation — particularly SIRT1 and SIRT3 — which regulate cellular repair processes including those maintaining skin integrity and collagen synthesis. Lower NAD+ means less efficient sirtuin-driven cellular repair.

A September 2025 clinical study in middle-aged women (40–50, ages aligning with perimenopause) found that 500mg daily NMN supplementation over 12 weeks significantly increased anagen hair density and hair diameter. This is an early and small study, but the biological mechanism is coherent — NAD+/sirtuin support for follicular cell function — and the population is directly relevant.

For skin specifically, I'd suggest combining NMN with our Collagen Complex 5-in-1: NMN addresses the cellular repair machinery (NAD+/sirtuins), collagen provides the structural building blocks. They work through complementary pathways.

Bone Health

Bone density loss accelerates significantly in the years following menopause, driven primarily by the loss of oestrogen's bone-protective effects. While NMN is not a bone health supplement in the conventional sense, there is emerging animal model evidence that NAD+/sirtuin pathways play a role in osteoblast function (bone formation), and that NAD+ depletion accelerates bone loss. This is an area where human evidence is still developing, but it adds to the biological case for NAD+ restoration in postmenopausal women as part of a broader approach to healthy ageing.

NMN and HRT: Complementary, Not Competing

I want to address this directly because it's a question I get asked. NMN is not an alternative to HRT for managing menopause. Hormone replacement therapy — where appropriate and where a woman chooses it — remains the most effective treatment for vasomotor symptoms (hot flushes, night sweats), genitourinary symptoms and bone protection. The clinical evidence for HRT in these areas is mature and robust.

NMN addresses a different biological dimension: the cellular metabolism and metabolic decline that runs alongside and beyond the hormonal changes of menopause. These are complementary concerns. A woman taking HRT can also benefit from NMN's metabolic and mitochondrial-related research. A woman not taking HRT may find NMN a useful part of a broader cellular health approach.

There are no known interactions between NMN and standard HRT preparations, though as always, discuss with your GP before starting any new supplement alongside prescription medication.

The Protocol I'd Recommend

Shop NMN Plus — from £9.99 → Shop Magnesium Glycinate — £9.99 → Shop Collagen Complex 5-in-1 — £9.99 →

---

This article is for informational purposes only and does not constitute medical advice. NMN is a food supplement, not a medicine. Menopause management should involve your GP or a menopause specialist. If you are considering HRT or other hormonal treatments, please discuss these with a qualified healthcare professional. Do not alter or stop any prescribed medication without medical advice.